Quest Diagnostics’ Retrenchment Gives Royalty Pharma A Stake In Ibrutinib

The royalty stream investor now has a stake in the highly anticipated cancer treatment that was recently submitted to FDA. The sale of the revenue stream is just another step in Quest’s efforts to refocus the company.